Huang, L., Shah, K., Barat, B., Lam, C.-Y.K., Gorlatov, S., Ciccarone, V., Tamura, J., Moore, P.A. and Diedrich, G. (2020) Multispecific, Multivalent Antibody-Based Molecules Engineered on the DART® and TRIDENT^TM Platforms. Current Protocols in Immunology, 129, e95.
https://doi.org/10.1002/cpim.95

has been cited by the following article:

• TITLE: Construction of Multi-Specific Antibody by Genetic Engineering and Its Progress in Tumor Therapy

  AUTHORS: Zhenqi Xu, Can Gao, Mengru Jian, Wei Du

  KEYWORDS: Genetically Engineered, Multi-Specific Antibody, Tumor Therapy

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.11 No.3, March 24, 2023

  ABSTRACT: Targeted treatment of cancer with monoclonal antibodies increases the benefit for patients. In order to improve the anti-tumor activity of monoclonal antibodies, multi-specific antibodies have entered the research field. The emergence of various techniques to produce multi-specific recombinant antibody molecules has led to the selection of target combinations in various forms. To date, only a few multi-specific constructs have entered phase III clinical trials, in contrast to classical monoclonal antibodies. Some of the format options are outlined from a technical point of view. We focus on the achievements and prospects of the underlying technologies for generating biand multispecific antibodies.